Previous 10 | Next 10 |
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal ...
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal...
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care and dermatologi...
2024-02-08 17:22:43 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals Read the full article on Seeking Alpha ...
Revenues increased 7% compared to quarter from prior year and 15% from prior quarter Improvement in gross margin for quarter of 19% compared to prior year Improvement in net loss for quarter of $1.0 million compared to prior year BOULDER, CO / ACCESSWIRE / February 8, 2024 / Sonom...
BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the launch of Lu...
EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova ® -branded products by Sonoma in the European Union. The new pr...
2023-11-14 01:37:04 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals For further details see: Sonoma Pharma...
Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year European revenues increased 3% for the quarter and 13% for the six months ended ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
News, Short Squeeze, Breakout and More Instantly...
Sonoma Pharmaceuticals Inc. Company Name:
SNOA Stock Symbol:
NASDAQ Market:
Sonoma Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Revenues increased 14% in Q4 2024 compared to Q4 2023 Gross profit margin improved 3% in FY 2024 compared to FY 2023 Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023 BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. ...